| New vaccine technologies to combat outbreak situations S Rauch, E Jasny Frontiers in immunology 9, 398616, 2018 | 678 | 2018 |
| Active sites of thioredoxin reductases: why selenoproteins? S Gromer, L Johansson, H Bauer, LD Arscott, S Rauch, DP Ballou, ... Proceedings of the National Academy of Sciences 100 (22), 12618-12623, 2003 | 233 | 2003 |
| mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents S Rauch, N Roth, K Schwendt, M Fotin-Mleczek, SO Mueller, B Petsch npj Vaccines 6 (1), 57, 2021 | 169 | 2021 |
| Multiple interactions between the ESCRT machinery and arrestin-related proteins: implications for PPXY-dependent budding S Rauch, J Martin-Serrano Journal of virology 85 (7), 3546-3556, 2011 | 145 | 2011 |
| A thermostable messenger RNA based vaccine against rabies L Stitz, A Vogel, M Schnee, D Voss, S Rauch, T Mutzke, T Ketterer, ... PLoS neglected tropical diseases 11 (12), e0006108, 2017 | 116 | 2017 |
| The HIV-1 pathogenicity factor Nef interferes with maturation of stimulatory T-lymphocyte contacts by modulation of N-Wasp activity C Haller, S Rauch, N Michel, S Hannemann, MJ Lehmann, OT Keppler, ... Journal of Biological Chemistry 281 (28), 19618-19630, 2006 | 108 | 2006 |
| Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine MS Gebre, S Rauch, N Roth, J Yu, A Chandrashekar, NB Mercado, X He, ... Nature 601 (7893), 410-414, 2022 | 98 | 2022 |
| Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains B Brügger, E Krautkrämer, N Tibroni, CE Munte, S Rauch, I Leibrecht, ... Retrovirology 4, 1-12, 2007 | 98 | 2007 |
| mRNA cancer vaccines K Fiedler, S Lazzaro, J Lutz, S Rauch, R Heidenreich Current Strategies in Cancer Gene Therapy, 61-85, 2016 | 91 | 2016 |
| cAMP synthesis and degradation by phagosomes regulate actin assembly and fusion events: consequences for mycobacteria SA Kalamidas, MP Kuehnel, P Peyron, V Rybin, S Rauch, OB Kotoulas, ... Journal of cell science 119 (17), 3686-3694, 2006 | 91 | 2006 |
| HIV-1 Nef employs two distinct mechanisms to modulate Lck subcellular localization and TCR induced actin remodeling C Haller, S Rauch, OT Fackler PloS one 2 (11), e1212, 2007 | 89 | 2007 |
| Lipid nanoparticle mrna vaccines P Baumhof, M Fotin-Mleczek, R Heidenreich, MJ Hope, E Jasny, ... US Patent App. 16/345,299, 2020 | 80 | 2020 |
| Modulation of specific surface receptors and activation sensitization in primary resting CD4+ T lymphocytes by the Nef protein of HIV‐1 OT Keppler, N Tibroni, S Venzke, S Rauch, OT Fackler Journal of leukocyte biology 79 (3), 616-627, 2006 | 78 | 2006 |
| Ebolavirus and marburgvirus vaccines S Rauch, E Jasny US Patent App. 15/536,595, 2017 | 76 | 2017 |
| Human immunodeficiency virus type 1 Nef recruits the guanine exchange factor Vav1 via an unexpected interface into plasma membrane microdomains for association with p21 … S Rauch, K Pulkkinen, K Saksela, OT Fackler Journal of virology 82 (6), 2918-2929, 2008 | 73 | 2008 |
| CTL-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef T Ueno, C Motozono, S Dohki, P Mwimanzi, S Rauch, OT Fackler, S Oka, ... The Journal of Immunology 180 (2), 1107-1116, 2008 | 67 | 2008 |
| Optimized nucleic acid molecules P Baumhof, S Rauch, A Kowalczyk, J Lutz, E Jasny, B Petsch, A Thess, ... US Patent App. 15/774,423, 2018 | 56 | 2018 |
| RNActive® technology: generation and testing of stable and immunogenic mRNA vaccines S Rauch, J Lutz, A Kowalczyk, T Schlake, R Heidenreich RNA Vaccines: Methods and Protocols, 89-107, 2017 | 51 | 2017 |
| MERS coronavirus vaccine S Rauch US Patent 11,141,476, 2021 | 49 | 2021 |
| mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection S Rauch, K Gooch, Y Hall, FJ Salguero, MJ Dennis, FV Gleeson, D Harris, ... Biorxiv, 2020.12. 23.424138, 2020 | 48 | 2020 |
